8 results on '"Patricia Rincon"'
Search Results
2. Abstract PS4-12: Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC)
- Author
-
Ivan Marquez-Rodas, Tatiana Massarrah, María del Monte-Millán, Patricia Rincon, Isabel Echavarria, Ana Isabel Ballesteros, S. Lizarraga, Coralia Bueno-Muiño, Lucía Villarejo, Uriel Bohn, José Ángel García Sáenz, Rocío Ramos-Medina, Blanca Herrero, Yolanda Jerez, Nerea Lobato, Sara López-Tarruella, Maria Cebollero, Miguel Martín, Ricardo González del Val, Fernando Salvador Moreno, Enrique Alvarez, María Isabel Palomero, Charles M. Perou, and Inmaculada Ocaña
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Cancer ,Estrogen receptor ,medicine.disease ,Carboplatin ,chemistry.chemical_compound ,Basal (phylogenetics) ,Breast cancer ,chemistry ,Docetaxel ,Internal medicine ,medicine ,business ,Triple-negative breast cancer ,medicine.drug - Abstract
Background: TNBC is a particularly aggressive subtype with high recurrence rates and poor long-term survival. Anthracycline-free regimens based on docetaxel plus carboplatin (TCb) achieve around 50-55% pathologic complete responses (pCR) which correlates with better survival outcomes. Identification of genomic predictors of response is key to individualize therapies for this heterogeneous breast cancer (BC) subgroup. FOXA1 is a pioneer factor for androgen (AR) and estrogen receptors (ER). Its under-expression has been linked to cancer stemness in TNBC and better prognosis in ER-positive BC. The differential expression of AR, FOXA1 and BRCA1 is associated with sensitivity to chemotherapy in TNBC patients. Data support the plasticity role of FOXA1 driving basal to luminal BC cells by inducing luminal genes but also by repressing the basal phenotype and thus, tumor aggressiveness, although its role as a biomarker in TNBC is still controversial. We have analyzed RNAseq data of FOXA1 and AR in a series of TNBC tumors homogenously treated with neoadjuvant TCb to study their correlation with survival and response. Methodology: 300 TNBC patients have been included in a multicenter, prospective, non-randomized trial aimed to identify predictors of response to TCb in the neoadjuvant setting (NCT01560663). 278/300 patients were evaluable. PAM50 subtypes (NanoString nCounter) and RNAseq (HiSeq2500) were analyzed for those patients with both available samples and evaluable pathological response (n=208). Correlations were studied by the Kendall method. Linear or logistic regressions were adjusted for univariant analysis depending on numerical or categorical response variables, respectively. Results: FOXA1 and AR were differentially expressed between basal and non-basal tumor subtypes (PAM50), being overexpressed in non-basal (p Citation Format: Sara López-Tarruella, María del Monte-Millán, Enrique Alvarez, Yolanda Jerez, José Ángel García Saenz, Isabel Echavarria, Fernando Moreno, Ivan Márquez-Rodas, Coralia Bueno-Muiño, Blanca Herrero, Maria Cebollero, Rocío Ramos-Medina, Nerea Lobato, Ricardo González del Val, Maria Isabel Palomero, Santiago Lizarraga, Uriel Bohn, Ana Isabel Ballesteros, Patricia Rincón, Tatiana Massarrah, Inmaculada Ocaña, Lucía Villarejo, Charles M Perou, Miguel Martin. Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS4-12.
- Published
- 2021
3. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
- Author
-
María del Monte-Millán, Patricia Rincon, Ivan Marquez-Rodas, Rebeca Bernat, José A. García-Sáenz, Isabel Echavarria, Paula Romero, Yolanda Jerez, Sara López-Tarruella, Rocío Ramos-Medina, Ricardo González del Val, Fernando Asensio, Eva González-Haba, Nerea Lobato, María Isabel Palomero, Miguel Martín, Fernando Salvador Moreno, Enrique Alvarez, Blanca Herrero, Tatiana Massarrah, Oscar Bueno, S. Lizarraga, and Maria Cebollero
- Subjects
Oncology ,medicine.medical_specialty ,endocrine system diseases ,Science ,PALB2 ,Triple Negative Breast Neoplasms ,Docetaxel ,urologic and male genital diseases ,Article ,Carboplatin ,chemistry.chemical_compound ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,Doxorubicin ,In patient ,Cancer models ,neoplasms ,Triple-negative breast cancer ,Cancer ,Multidisciplinary ,business.industry ,organic chemicals ,medicine.disease ,Xenograft Model Antitumor Assays ,chemistry ,Toxicity ,Medicine ,Female ,business ,therapeutics ,medicine.drug - Abstract
Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of each of these agents to the global activity of the combinations, and the use of combinations of up to four of these drugs is associated with relevant toxicity. Identifying single-drug activity in the clinical neoadjuvant setting is challenging. We developed patient-derived xenografts (PDXs) from several chemotherapy-naïve TNBC samples to assess the antitumor activity of single drugs and combinations of drugs. PDXs were established from chemotherapy-naïve TNBC samples. Nine TNBC PDX models (all of which corresponded to a basal-like phenotype according to the PAM50 classifier) were treated with carboplatin, docetaxel, and doxorubicin and the combination of docetaxel and carboplatin. Only one of nine PDX models showed sensitivity to doxorubicin, while eight of nine PDX models showed sensitivity to docetaxel and carboplatin as single agents. The 3 PDX models derived from patients with gBRCA-1 or gPALB2 mutations were very sensitive to carboplatin single agent. All 6 PDX models from patients without hereditary germ-line mutations showed increased sensitivity to the combination of docetaxel and carboplatin. In the present study, docetaxel and carboplatin single agents were active drugs against basal-like TNBC, while doxorubicin monotherapy showed low activity. The combination of docetaxel and carboplatin was more effective than the drugs used as single agents, except in the PDX from patients with gBRCA1/PALB2 mutations.
- Published
- 2020
4. Activity Of Docetaxel, Carboplatin, And Doxorubicin In Patient-Derived Triple-Negative Breast Cancer Xenografts
- Author
-
Miguel Martin, Rocio Ramos-Medina, Rebeca Bernat, Jose Angel Garcia Saenz, Maria Del Monte-Millan, Enrique Alvarez, Maria Cebollero, Fernando Moreno, Eva Gonzalez Haba, Oscar Bueno, Paula Romero, Tatiana Massarrah, Isabel Echavarria, Yolanda Jerez, Blanca Herrero, Ricardo Gonzalez Del Val, Nerea Lobato, Patricia Rincon, Maria Isabel Palomero, Ivan Marquez-Rodas, Santiago Lizarraga, Fernando Asensio, and Sara Lopez-Tarruella
- Subjects
endocrine system diseases ,organic chemicals ,urologic and male genital diseases ,therapeutics ,neoplasms - Abstract
Background: Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of each of these agents to the global activity of the combinations, and the use of combinations of up to four of these drugs is associated with relevant toxicity. Identifying single-drug activity in the clinical neoadjuvant setting is challenging. We developed patient-derived xenografts (PDXs) from several chemotherapy-naïve TNBC samples to assess the antitumor activity of single drugs and combinations of drugs. Methods: PDXs were established from chemotherapy-naïve TNBC samples. Nine TNBC PDX models (all of which corresponded to a basal-like phenotype according to the PAM50 classifier) were treated with carboplatin, docetaxel, and doxorubicin and the combination of docetaxel and carboplatin. Results: Only one of nine PDX models showed sensitivity to doxorubicin, while eight of nine PDX models showed sensitivity to docetaxel and carboplatin as single agents. All nine PDX models showed sensitivity to the combination of docetaxel and carboplatin. Conclusions: In the present study, docetaxel and carboplatin single agents were active drugs against basal-like TNBC, while doxorubicin monotherapy showed low activity. The combination of docetaxel and carboplatin was more effective than the drugs used as single agents.
- Published
- 2020
5. Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation
- Author
-
M.I. Palomero Plaza, Sara López-Tarruella, I. Márquez-Rodas, S. Lizarraga, Ana Calin, C. Flores Sanchez, M. Martin, Patricia Rincon, R. Gonzalez del Val, Yolanda Jerez, I. Echavarria Diaz-Guardamino, Elsa Mendizabal, Antonio José Morales Hernández, Oscar Bueno, Gioconda García, J.A. Blanco, Maria Cebollero, Miriam Lobo, S. Perez Ramirez, and S. Luque
- Subjects
medicine.medical_specialty ,Breast cancer ,Oncology ,Multidisciplinary approach ,business.industry ,Medicine ,Cancer ,Hematology ,Genetic risk ,business ,medicine.disease ,Intensive care medicine ,Unit (housing) - Published
- 2016
6. The implementation of a multidisciplinary heredofamilial cancer unit to increase the referral and preventive surgeries of breast cancer patients with genetic risk in a university hospital
- Author
-
Ricardo González del Val, Patricia Rincon, Yolanda Jerez, Elsa Mendizabal, Iria Gallego, Oscar Bueno, Carmen Flores Sanchez, S. Lizarraga, Angel Hernandez, Isabel Echavarria Diaz Guardamino, Isabel Palomero, Sara López-Tarruella, Sara Perez Ramirez, Ana Calin, Miguel Martín, Soledad Luque Molina, Maria Cebollero, Ivan Marquez Rodas, Miriam Lobo de Mena, and J. M. Blanco
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,Referral ,business.industry ,Cancer ,medicine.disease ,University hospital ,Unit (housing) ,Breast cancer ,Oncology ,Multidisciplinary approach ,Emergency medicine ,medicine ,Genetic risk ,business - Abstract
e13031Background: The identification of patients with Breast Cancer (BC) and genetic risk has proved a positive impact in reducing the mortality for BC and the prevention of second tumors. In 2010,...
- Published
- 2016
7. First one thousand families: Our multidisciplinary experience in the heredo-familial cancer unit from a Spanish University Hospital
- Author
-
Mercedes Sanz, S. Lizarraga, Jesus Solera, Cristina López López, Sara López-Tarruella, Oscar Bueno, Patricia Rincon, Miguel Martin, Maria Die Trill, Aitana Calvo, Cecilia González Asanza, Andres J. Muñoz Martín, Maria Isabel Peligros, Soledad Luque Molina, Cristina Mata, Jose Antonio Pajares, Yolanda Jerez Gilarranz, Carmen Flores Sanchez, Pedro Menchén, and Ivan Marquez Rodas
- Subjects
Cancer Research ,Pediatrics ,medicine.medical_specialty ,Oncology ,Hereditary Cancer Syndromes ,Multidisciplinary approach ,business.industry ,Medicine ,Familial Cancer ,University hospital ,business ,Unit (housing) - Abstract
1556 Background: Patients with hereditary cancer syndromes (HCS) need a multidisciplinary approach: Different organs and systems may be involved and different risk reducing strategies (medical and ...
- Published
- 2015
8. The Village AIDS Day Treatment Program: a model of interdisciplinary and interdependent care
- Author
-
Thomas Martin, Elizabeth Getter, Jan Zimmerman, Linda Gutterman, William Messina, Patricia Rincon, and Nancy Murphy
- Subjects
Gerontology ,Patient Care Team ,Acquired Immunodeficiency Syndrome ,business.industry ,media_common.quotation_subject ,Interprofessional Relations ,Human immunodeficiency virus (HIV) ,Health Promotion ,medicine.disease ,medicine.disease_cause ,Interdependence ,Occupational Therapy ,Acquired immunodeficiency syndrome (AIDS) ,Nursing ,Health care ,Preventive Health Services ,medicine ,Day treatment ,Humans ,business ,Delivery of Health Care ,media_common - Abstract
This article describes the Village AIDS Day Treatment Program, a program for people living with HIV/AIDS that provides health care by using a full range of interdependent services. Opened in 1988, this program was the first of its kind in the country. It has provided leadership in developing a model of care that addresses the full spectrum of health care—promotion, prevention, maintenance, and treatment. Along with describing the program and its services, this article includes the program’s history and its influencing philosophies.
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.